UPDATE: Aegis Capital Reiterates Buy Rating, Raises PT on China Biologic Products
In a report published Friday, Aegis Capital Corp. reiterated its Buy rating on China Biologic Products (NASDAQ: CBPO), and raised its price target to $22.00 price target.
Aegis Capital noted, “Recently, China's National Development and Reform Commission (NDRC) announced a new round of maximum retail price adjustment for drugs in the categories of respiratory, antipyretic, analgesic and specialty medications, with average price reduction of 15%, effective on Feb 1st, 2013. Interestingly, price ceilings for plasma-based products were raised. Notably, prices for various doses of human albumin would see an increase of approximately 5%. We note that the price ceiling of 10g/50ml human albumin, which is used as a representative by NDRC, was set at ¥330 in 2000 and reduced to ¥259 in 2006. However, it was raised to ¥360 in 2007 to balance the short supply and strong demand, with imported human albumin being allowed to charge 5% more. The current price of ¥378 essentially lets domestic manufacturers charge the same price as their foreign counterparts in China. Human albumin represents 54.5% and 45.3% of China Biologic's 2011 and 9-month 2012 total revenue, respectively.”
China Biologic Products closed on Thursday at $18.90.
Latest Ratings for CBPO
|Mar 2016||Credit Suisse||Downgrades||Outperform||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.